Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹4,704 Cr
Revenue (TTM)
₹735 Cr
Net Profit (TTM)
₹185 Cr
ROE
20.7 %
ROCE
27.6 %
P/E Ratio
25.4
P/B Ratio
4.2
Industry P/E
28.4
EV/EBITDA
16.7
Div. Yield
0.2 %
Debt to Equity
0
Book Value
₹140.6
EPS
₹23.1
Face value
2
Shares outstanding
80,482,800
CFO
₹699.78 Cr
EBITDA
₹1,173.75 Cr
Net Profit
₹805.24 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Supriya Lifescience
| -22.3 | -14.7 | -20.8 | -11.5 | 44.1 | -- | -- |
|
BSE Healthcare
| -2.6 | -1.7 | -3.7 | 3.2 | 25.2 | 15.5 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Supriya Lifescience
| -0.7 | 135.0 | 33.9 | -51.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Supriya Lifescience
|
584.2 | 4,704.2 | 735.5 | 185.3 | 32.4 | 17.9 | 25.4 | 4.2 |
| 2,904.7 | 37,130.9 | 5,201.6 | 1,014.6 | 22.9 | 25 | 36.6 | 8.1 | |
| 8,321.0 | 20,755.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 103.3 | 25.0 | |
| 1,604.1 | 12,230.3 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.9 | 3.7 | |
| 1,284.9 | 17,969.7 | 3,078.2 | 469.4 | 26.4 | 14.9 | 41.6 | 5.0 | |
| 2,138.6 | 34,607.6 | 4,193.0 | 753.8 | 22.7 | 20.8 | 45.9 | 8.6 | |
| 4,773.5 | 21,779.6 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.5 | 5.5 | |
| 4,860.6 | 8,091.5 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.6 | 11.6 | |
| 3,386.1 | 7,784.4 | 1,837.4 | 326.7 | 24.7 | 45.3 | 23.8 | 10.4 | |
| 903.7 | 8,388.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 16.4 | 2.8 |
Supriya Lifescience IPO: How good is it?
5 min read•By Udhayaprakash and Karthik Anand Vijay
Supriya Lifescience IPO: Information analysis
3 min read•By Udhayaprakash and Karthik Anand Vijay
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic,... decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India. Read more
Incorporated
2008
Chairman
Satish Waman Wagh
Managing Director
Saloni Satish Wagh
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Supriya Lifescience Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Supriya Lifescience Ltd is ₹584.20 (NSE) and ₹583.50 (BSE) as of 20-Mar-2026 IST. Supriya Lifescience Ltd has given a return of 44.09% in the last 3 years.
The P/E ratio of Supriya Lifescience Ltd is 25.39 times as on 20-Mar-2026, a 11 discount to its peers’ median range of 28.40 times.
The P/B ratio of Supriya Lifescience Ltd is 4.16 times as on 20-Mar-2026, a 7 discount to its peers’ median range of 4.48 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
31.41
|
5.92
|
|
2024
|
22.42
|
3.27
|
|
2023
|
17.08
|
2.19
|
|
2022
|
26.13
|
6.44
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Supriya Lifescience Ltd are Rs 842.00 and Rs 565.00 as of 20-Mar-2026.
Supriya Lifescience Ltd has a market capitalisation of ₹ 4,704 Cr as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Supriya Lifescience Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹4.30
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.